Forvis Mazars Wealth Advisors LLC Sells 128 Shares of Stryker Corporation $SYK

Forvis Mazars Wealth Advisors LLC cut its holdings in Stryker Corporation (NYSE:SYK) by 0.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,838 shares of the medical technology company’s stock after selling 128 shares during the period. Forvis Mazars Wealth Advisors LLC’s holdings in Stryker were worth $5,870,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Mar Vista Investment Partners LLC boosted its holdings in Stryker by 10.2% in the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock worth $33,572,000 after purchasing an additional 8,353 shares in the last quarter. United Services Automobile Association bought a new stake in shares of Stryker in the first quarter valued at about $2,857,000. AXS Investments LLC lifted its stake in shares of Stryker by 13.7% in the first quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after buying an additional 1,062 shares during the period. Park Edge Advisors LLC bought a new stake in shares of Stryker in the second quarter valued at about $679,000. Finally, Hendley & Co. Inc. lifted its stake in Stryker by 60.3% during the second quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock worth $5,546,000 after purchasing an additional 5,274 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

Shares of Stryker stock opened at $374.67 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm has a market cap of $143.24 billion, a P/E ratio of 49.63, a P/E/G ratio of 2.70 and a beta of 0.94. The firm has a 50 day simple moving average of $379.40 and a 200 day simple moving average of $378.77. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on SYK shares. Needham & Company LLC raised their price target on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Redburn Partners set a $420.00 price target on shares of Stryker in a research note on Thursday, September 18th. Evercore ISI dropped their price objective on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Rothschild & Co Redburn started coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective for the company. Finally, Wells Fargo & Company raised their price objective on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $431.76.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.